Blood transfusions are one of the most common procedures performed in hospitalized patients. Yet, despite all of the measures taken to ensure the safety of the blood supply, there are known risks associated with transfusions, including infectious and noninfectious complications. Meanwhile, issues with blood product availability, the need for compatibility testing, and the storage and transport requirements of blood products, have presented challenges for the administration of blood transfusions. Additionally, there are individuals who do not accept blood transfusions (e.g., Jehovah's Witnesses). Therefore, there is a need to develop alternative agents that can reliably and safely replace blood. However, although there have been many attempts to develop blood substitutes over the years, there are currently no such products available that have been approved by the United States Food and Drug Administration (FDA). However, a more-recently developed hemoglobin-based oxygen carrier has shown promise in early clinical trials and has achieved the status of "Orphan Drug" under the FDA.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086064 | PMC |
http://dx.doi.org/10.15190/d.2020.1 | DOI Listing |
HLA
January 2025
School of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina.
The novel HLA-C*06:44:02 allele differs from HLA-C*06:44:01 by one synonymous nucleotide substitution in exon 2.
View Article and Find Full Text PDFHLA
January 2025
Department of Transfusion Research, Wuhan Blood Center, Wuhan, China.
HLA-B*15:245:02Q differs from HLA-B*15:01:01:01 by two nonsynonymous nucleotides exchanges in exon 3.
View Article and Find Full Text PDFHLA
January 2025
Department of Transfusion, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
HLA-B*37:114 has a single non-synonymous change from HLA-B*37:01:01:01 changing residue 163 from Threonine to Lysine'.
View Article and Find Full Text PDFTransfusion
January 2025
Association for the Advancement of Blood and Biotherapies, Bethesda, Maryland, USA.
Background: The Association for the Advancement of Blood and Biotherapies (AABB) conducted a global survey of patient blood management (PBM) practices. It determined changes in PBM practices since the last survey.
Study Design And Methods: A working group of AABB's PBM Subsection and AABB staff designed the survey using the Qualtrics™ platform.
Transfus Med
January 2025
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
Objectives: Trauma-induced coagulopathy (TIC) can be fatal but preventable if recognised early. With emerging uses of rotational thromboelastometry (ROTEM) to guide transfusions in trauma, patient outcomes with TIC-defined by initial ROTEM and conventional coagulation tests (CCTs) during massive haemorrhage protocol (MHP) activations were evaluated at a primary trauma centre in British Columbia.
Methods: This retrospective observational study included adult trauma patients requiring MHP from June 1, 2020, to May 31, 2022.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!